X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast VersaFilm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
The agreement aims for the co-development and commercialization of cannabinoid-infused VersaFilm® products, including CBD VersaFilm (cannabinoid), a unique drug opportunity for the treatment of neurodegenerative diseases of the brain.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: CBD VersaFilm
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tilray
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 06, 2023
Details:
VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast VersaFilm
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast VersaFilm
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karolinska University Hospital
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 25, 2023
Details:
Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karolinska Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2023
Details:
Resumption of patient dosing in the ongoing Phase 2a (BUENA) clinical trial of Montelukast VersaFilm, a leukotriene receptor antagonist on the basis of Phase 1 study data that reduces the first-pass-effect and has a 52% higher bioavailability.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Montelukast-Generic
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
In Phase 1 studies, an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Data suggest Montelukast may inhibit mental decline, higher doses optimal for clinical trials assessing impact on neurological disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory response insevere COVID-19.
Lead Product(s): Zileuton,Montelukast Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyflo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Health Canada has issued a No Objection Letter in response to IntelGenx’s amended Clinical Trial Application for the ongoing Montelukast VersaFilm® Phase 2a clinical trial for Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
